ZYBERNO
Stock Report
Updated Aug 31, 2026

PLIANT THERAPEUTICS, INC. (PLRX)

Healthcare • NASDAQ

$1.10

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
19.0/100
POOR BUSINESS
PLIANT THERAPEUTICS, INC. (PLRX) scores 19/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-53.2%)
Debt-to-Equity (Solvency Risk):GOOD (0.39x)
Operating Margin (Operational Efficiency):CRITICAL (-6,169.6%)
Return on Capital (Capital Efficiency):CRITICAL (-48.5%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

PLIANT THERAPEUTICS, INC. (PLRX) stock report — Zyberno Score 19/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, PLRX generated -$98.81M in Owner Earnings. Capital was deployed as follows: $112.00K invested in capital expenditures. Reinvestment rate: 1.8%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.10
Market Cap:$68.11M

Valuation Multiples (3)

P/B Ratio:0.46x
P/S Ratio:43.11x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$71.97M

Price Action & Momentum (3)

Momentum Percentile:35 / 100
% of 52-Week High:56.4%
B. Profitability Assessment

Return Metrics (5)

ROA:-41.3%
Reinvestment Rate:1.8%
Fundamental Growth Rate (g):-0.9%

Margin Analysis (3)

Operating Margin Ttm:-6,169.6%
Net Margin Ttm:-5,841.1%
Ebitda Margin:-6,086.6%

TTM Performance (2)

Operating Margin Ttm:-6,169.6%
Net Margin Ttm:-5,841.1%

Yield Metrics (2)

Earnings Yield:-$137.04
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:44.3%
Latest Earnings Filed:2026-08-11

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-38.6%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:9.90x
Quick Ratio:9.90x
Cash Ratio:1.51x

Leverage Analysis (3)

Debt To Equity Ttm:0.39x
Debt-to-Equity Ratio:0.39x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-164.43x
Times Interest Earned:-164.43

Capital Structure (4)

Working Capital:146,658,000.00
Cash And Cash Equivalents:24,883,000.00
Long Term Debt:$26.47M
Net Debt:$3.86M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $1.58M
Linear Growth: -38.6%
📊 Click to view full PLRX Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$97.48M

Bottom Line Performance (3)

-$92.29M
Income Before Tax:-$149.30M
Ebitda Ttm:-96,168,000.00

Operating Expenses (5)

Operating Expenses:97,480,000.00
R And D Expense:63,834,000.00
Sga Expense:33,646,000.00
Income Tax Expense:$0.00
Interest Expense:951,000.00

Expense Ratios (1)

Ebitda Margin:-6,086.6%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$189.88M
Current Assets:$163.14M
Ppe Net:13,102,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:42,955,000.00
Current Liabilities:16,484,000.00
Long Term Debt:$26.47M
Short Term Debt:$2.27M

Equity & Capital (3)

Equity:$146.93M
Retained Earnings:-$901.81M
Common Stock:300,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:1,531,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:4,186,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$98.70M-$98.81M

Investment Activities (2)

Investing Cash Flow:-$4.10M
Capital Expenditures Ttm:112,000.00

Financing Activities (3)

Financing Cash Flow:$74.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$32.27M

Non-Cash Items (1)

Depreciation Amortization Ttm:1,312,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.48
-$1.48
Earnings Per Share Ttm:-$1.49

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.03
Operating Cash Flow Per Share:-$2.07

Book Value & Capital (2)

Book Value Per Share:$2.37
Cash Per Share:0.40

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.01x
Working Capital Turnover Ttm:0.01x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:353.68
Cash Conversion Cycle:-2,351.68
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$98.81M

Damodaran Growth Analysis (2)

Reinvestment Rate:1.8%
Fundamental Growth Rate (g):-0.9%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-38.6%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-11.8%
C. Company Profile & Context

Corporate Information (6)

Symbol:PLRX
Company Name:PLIANT THERAPEUTICS, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:61.92M
Shares Outstanding Basic:61.92M
Shares Outstanding Diluted:61.92M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 22:25:55 UTC
Data Timestamp:2026-08-20T01:27:37.124339
Scroll to Top